GLI1 and familial pancreatic carcinoma: The concept that HH/GLI1 signaling might be required for PDAC growth, hence a suitable therapeutic target, has been first validated in a genetically engineered mouse model of pancreatic cancer that combines expression of oncogenic Kras with mutation of the tumor suppressor p53, the KPC mouse (Hingoraniet al., 2005).